Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 21 Lung Neoplasms 10 Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Skin Neoplasms 6 Prostatic Neoplasms 5 Neoplasm Metastasis 5 Melanoma 5 Head and Neck Neoplasms 5 Urinary Bladder Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Renal Cell 4 Carcinoma, Merkel Cell 4 Breast Neoplasms 4 Sarcoma 3 Pancreatic Neoplasms 3 Mycosis Fungoides 3 Carcinoma, Squamous Cell 3 Carcinoma, Hepatocellular 3 Carcinoma, Basal Cell 3 Adenocarcinoma 3 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 2 Thyroid Carcinoma, Anaplastic 2 Rectal Neoplasms 2 Oropharyngeal Neoplasms 2 Mouth Neoplasms 2 Mesothelioma, Malignant 2 Lymphoma, T-Cell 2 Lymphoma, Large-Cell, Anaplastic 2

Interventions

Pemetrexed 9 Drug Therapy 9 osimertinib 7 Radiotherapy 6 Carboplatin 6 anlotinib 5 Radiosurgery 5 aflutinib 4 Gefitinib 4 Docetaxel 4 Cisplatin 4 tislelizumab 3 pembrolizumab 3 icotinib 3 Vinorelbine 3 Paclitaxel 3 Gemcitabine 3 Erlotinib Hydrochloride 3 toripalimab 2 dacomitinib 2 camrelizumab 2 apatinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Liquid Biopsy 2 Immune Checkpoint Inhibitors 2 Chemotherapy, Adjuvant 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × NSCLC × cemiplimab × Clear all

NCT06865339 2026-04-13

TRIPL

Montefiore Medical Center

Phase 2 Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡